SHANGHAI

上海

,

，

Aug. 4, 2026

2026年8月4日

/PRNewswire/ --

/美通社/ --

AsymBio

艾森生物

, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of

，一家专注于生物制品的合同开发与制造组织（CDMO），且为

Asymchem Group

凯莱英集团

(stock codes: 002821.SZ / 6821.HK), today announced a total capital injection of RMB 1.2397 billion (approximately US$184 million) into AsymBio by Asymchem Group, Hillhouse Qirui and other investors.

（股票代码：002821.SZ / 6821.HK），今日宣布，药明康德集团、高瓴启瑞及其他投资者向合源生物注资总计人民币12.397亿元（约合1.84亿美元）。

Upon completion of the capital increase, Asymchem Group's shareholding in AsymBio will increase to 83.4965%. The transaction reflects strong confidence in AsymBio's differentiated CDMO strategy and its long-term potential to support global pharmaceutical and biotechnology companies advancing complex biologics programs..

增资完成后，凯莱英集团对凯莱博瑞的持股比例将增至83.4965%。此次交易体现了对凯莱博瑞差异化CDMO战略及其在支持全球制药和生物技术公司推进复杂生物药项目方面长期潜力的坚定信心。

Of the total capital injection, Asymchem Group will contribute RMB 1.05 billion (approximately US$156 million), while Hillhouse Qirui will contribute RMB 177 million (approximately US$26 million). Hillhouse Qirui's significant participation underscores its long-term confidence in AsymBio and the biologics CDMO sector.

在总注资额中，凯莱英集团将出资人民币10.5亿元（约1.56亿美元），而高瓴祺瑞将出资人民币1.77亿元（约2,600万美元）。高瓴祺瑞的大规模参与彰显了其对合全药业以及生物药CDMO领域的长期信心。

.

。

Hillhouse has a long track record of investing

高瓴资本拥有长期的投资业绩记录

across the biopharmaceutical value chain and the broader global healthcare sector. Its investment aligns with Asymchem Group's differentiated, one-stop, end-to-end CDMO strategy.

贯穿生物制药价值链及更广泛的全球医疗健康领域。其投资与药明康德差异化的、一站式、端到端的CDMO战略相契合。

Globally, pipelines involving antibody-drug conjugates (ADCs), novel drug conjugates (NDCs), and bispecific and multispecific antibodies are advancing rapidly into clinical development. At the same time, outsourcing demand from biotech companies and large pharmaceutical companies in China and global markets continues to expand..

在全球范围内，涉及抗体偶联药物（ADCs）、新型偶联药物（NDCs）以及双特异性与多特异性抗体的研发管线正迅速推进至临床开发阶段。与此同时，中国及全球市场的生物科技公司和大型制药企业的外包需求持续扩大。

AsymBio's growth momentum is evident in its operating performance. The Company generated approximately RMB 470 million (approximately US$70 million) in revenue in 2025, with first-quarter 2026 revenue exceeding RMB 140 million (approximately US$21 million).

AsymBio的增长势头在其经营业绩中显而易见。该公司2025年产生约人民币4.7亿元（约7,000万美元）的收入，2026年第一季度收入超过人民币1.4亿元（约2,100万美元）。

As a growing biologics CDMO, AsymBio has continued to invest in R&D platforms, GMP manufacturing lines and high-potency, high-containment facilities. The new capital will be directed toward its core business to support capacity ramp-up and the scaled delivery of client programs, driving greater operating leverage and a clearer path toward profitability..

作为一家不断成长的生物药合同研发生产组织（CDMO），AsymBio 持续投入研发平台、GMP 生产线以及高活性、高密闭性设施。新资金将投向其核心业务，以支持产能提升和客户项目的大规模交付，从而增强经营杠杆效应，并铺设更清晰的盈利路径。

About AsymBio

关于AsymBio

AsymBio, a subsidiary of Asymchem Group (stock codes: 002821.SZ / 6821.HK), focuses exclusively on biopharmaceutical CDMO services. Backed by Asymchem Group's 30 years of experience and global operations, AsymBio delivers one-stop CDMO services from early-stage and process development to toxicology, clinical, and commercial-scale manufacturing.

凯莱英集团（股票代码：002821.SZ / 6821.HK）旗下子公司AsymBio专注于生物制药合同研发生产服务（CDMO）。依托凯莱英集团30年的行业经验与全球化运营优势，AsymBio提供从早期工艺开发、毒理学研究、临床试验到商业化生产的一站式CDMO服务。

Building on deep ADC experience, AsymBio is expanding into NDCs, including RDCs, AOCs, APCs, BsADCs, and dpADCs, while maintaining comprehensive service capabilities for antibody therapeutics, including monoclonal, bispecific, and multispecific antibodies, and protein-based therapeutics, including fusion proteins and recombinant proteins..

依托深厚的抗体偶联药物（ADC）研发经验，药明合联正将业务拓展至核酸偶联药物（NDCs），包括放射性核素偶联药物（RDCs）、抗体寡核苷酸偶联物（AOCs）、抗体多肽偶联物（APCs）、双特异性抗体偶联药物（BsADCs）以及位点特异性抗体偶联药物（dpADCs），同时保持对各类抗体疗法（包括单克隆抗体、双特异性抗体和多特异性抗体）及蛋白质类疗法（包括融合蛋白和重组蛋白）的全面服务能力。

For more information, visit

更多信息，请访问

www.asymbio.com

www.asymbio.com

or follow us on

或在以下平台关注我们

LinkedIn

领英

.

。

Business inquiries:

商务咨询：

[email protected]

[email protected]

Compliance Notes

合规说明

Forward-Looking Statement Disclaimer:

前瞻性陈述免责声明：

This press release contains forward-looking statements regarding future events and expectations. Actual results may differ materially due to various factors. AsymBio undertakes no obligation to update these statements.

本新闻稿包含有关未来事件和预期的前瞻性陈述。由于各种因素，实际结果可能与预期存在重大差异。AsymBio 没有义务更新这些陈述。

Non-Solicitation Statement:

禁止招揽声明：

This announcement is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities.

本公告仅供信息参考，不构成投资建议，也不构成购买或出售证券的要约。

SOURCE AsymBio

来源：AsymBio

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

请求演示